Arbutus Biopharma (ABUS) Stock Price Up 9.5%

Shares of Arbutus Biopharma (NASDAQ:ABUS) rose 9.5% during mid-day trading on Friday . The company traded as high as $5.40 and last traded at $5.20. Approximately 502,356 shares traded hands during mid-day trading, an increase of 174% from the average daily volume of 183,634 shares. The stock had previously closed at $4.75.

A number of equities analysts have recently commented on ABUS shares. BidaskClub cut Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, February 3rd. B. Riley started coverage on Arbutus Biopharma in a report on Friday, January 5th. They issued a “buy” rating and a $10.00 target price for the company. ValuEngine cut Arbutus Biopharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 15th. Wedbush cut Arbutus Biopharma from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $9.00 to $6.00 in a report on Monday. Finally, Zacks Investment Research cut Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. Arbutus Biopharma currently has a consensus rating of “Hold” and an average target price of $12.38.

The company has a market capitalization of $242.31, a price-to-earnings ratio of -3.35 and a beta of 1.02. The company has a debt-to-equity ratio of 0.09, a current ratio of 8.85 and a quick ratio of 11.03.

Arbutus Biopharma (NASDAQ:ABUS) last announced its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.51). The company had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $0.70 million. Arbutus Biopharma had a negative return on equity of 55.28% and a negative net margin of 796.23%. equities analysts anticipate that Arbutus Biopharma will post -1.59 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. RTW Investments LP boosted its holdings in Arbutus Biopharma by 1.1% during the 3rd quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after acquiring an additional 56,457 shares during the period. BlackRock Inc. boosted its holdings in Arbutus Biopharma by 7,615.3% during the 4th quarter. BlackRock Inc. now owns 751,314 shares of the biopharmaceutical company’s stock valued at $3,794,000 after acquiring an additional 741,576 shares during the period. Renaissance Technologies LLC boosted its holdings in Arbutus Biopharma by 150.7% during the 4th quarter. Renaissance Technologies LLC now owns 402,573 shares of the biopharmaceutical company’s stock valued at $2,033,000 after acquiring an additional 241,963 shares during the period. Hudson Bay Capital Management LP boosted its holdings in Arbutus Biopharma by 239.0% during the 4th quarter. Hudson Bay Capital Management LP now owns 400,000 shares of the biopharmaceutical company’s stock valued at $2,020,000 after acquiring an additional 282,000 shares during the period. Finally, K2 Principal Fund L.P. boosted its holdings in Arbutus Biopharma by 4.5% during the 4th quarter. K2 Principal Fund L.P. now owns 261,326 shares of the biopharmaceutical company’s stock valued at $1,320,000 after acquiring an additional 11,311 shares during the period. Institutional investors own 62.14% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Arbutus Biopharma (ABUS) Stock Price Up 9.5%” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3294204/arbutus-biopharma-abus-stock-price-up-9-5.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Maxim Integrated  Releases Quarterly  Earnings Results, Beats Expectations By $0.03 EPS
Maxim Integrated Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
Rogers  Issues Q2 Earnings Guidance
Rogers Issues Q2 Earnings Guidance
Independence Realty Trust  Announces  Earnings Results, Misses Expectations By $0.14 EPS
Independence Realty Trust Announces Earnings Results, Misses Expectations By $0.14 EPS
EQT  Sees Unusually-High Trading Volume
EQT Sees Unusually-High Trading Volume
ProAssurance  Given Average Rating of “Hold” by Analysts
ProAssurance Given Average Rating of “Hold” by Analysts
$113.05 Million in Sales Expected for AeroVironment  This Quarter
$113.05 Million in Sales Expected for AeroVironment This Quarter


© 2006-2018 Ticker Report. Google+.